Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.38 |
| ▸ | RARB | P10826 | 8/20 | 0.38 |
| ▸ | RARG | P13631 | 8/20 | 0.38 |
| ▸ | RARA | P10276 | 7/20 | 0.38 |
| ▸ | RXRB | P28702 | 11/20 | 0.37 |
| ▸ | RXRG | P48443 | 11/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032727 | 0.81 | RXRA (0.36) | RXRARARBRARGRARARXRB | |
| SCHEMBL6032725 | 0.80 | RXRA (0.36) | RXRARARBRARGRARARXRB | |
| SCHEMBL6033003 | 0.80 | RXRA (0.41) | RXRARARBRARGRARARXRB | |
| SCHEMBL6563187 | 0.80 | RXRA (0.36) | RXRARARBRARGRARARXRB | |
| SCHEMBL6033044 | 0.79 | RXRA (0.59) | RXRARARBRARGRARARXRB | |
| SCHEMBL6032730 | 0.78 | RXRA (0.47) | RXRARARBRARGRARARXRB | |
| SCHEMBL6033264 | 0.77 | RARA (0.48) | RXRARARBRARGRARARXRB | |
| SCHEMBL6033243 | 0.76 | RXRA (0.46) | RXRARARBRARGRARARXRB | |
| SCHEMBL6542003 | 0.75 | RXRA (0.44) | RXRARARBRARGRARARXRB | |
| SCHEMBL13480474 | 0.73 | RXRA (0.65) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1086080-B1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2004-08-25 | — | — | EP | claimed |
| EP-1086080-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2001-03-28 | — | — | EP | claimed |
| WO-1999065872-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-12-23 | — | — | WO | claimed |
| US-6992094-B1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1086080-B1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2004-08-25 | — | — | EP | disclosed |
| EP-1086080-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065872-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | TYR, DERL1, GPX1 | RXRA 1865/4885RARB 2125/4885RARG 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.